Hansoh Pharma, a leading innovation-driven pharmaceutical company in the PRC, is committed to improving human health through unremitting innovation, focusing mainly on such areas as anti-tumor, anti-infectives, CNS diseases, metabolic diseases, autoimmune diseases.
After more than 20 years of continuous investment in R&D, Hansoh Pharma has marketed 7 innovative drugs and has over 30 innovative drug programs in different clinical stages with over 50 clinical trials in progress, forming a rich pipeline.
Find the latest and most complete information about Hansoh Pharma!
Hansoh Pharma has always focused on corporate governance, corporate behavior, product safety and quality, access to healthcare, human resource development, environmental protection and community enhancement as the focus and the basis of ESG management, and has been continually committed to improving the medicine availability and the innovative development in fields with unmet clinical needs.
We welcome talents worldwide to join us with their entrepreneurship and achieve new levels of success in their career!
INDICATIONS AND USAGE
Bortezomib for injection is a proteasome inhibitor indicated for:
• treatment of adult patients with multiple myeloma
• treatment of adult patients with mantle cell lymphoma
